Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York. Show more

Location: 2500 Westchester Ave., Purchase, NY, 10577, United States | Website: https://www.cogrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

35.17M

52 Wk Range

$0.22 - $2.54

Previous Close

$0.70

Open

$0.64

Volume

9,277,803

Day Range

$0.56 - $0.66

Enterprise Value

3.412M

Cash

16.43M

Avg Qtr Burn

-7.777M

Insider Ownership

0.81%

Institutional Own.

18.79%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.